Clinical Trial Update: A Study of MB-CART19.1 Cellular Therapy for People With Central Nervous System Lymphoma (CNSL) [Phase 1]

View source ↗

Summary

Phase 1 clinical trial evaluating MB-CART19.1 cellular therapy for primary and secondary central nervous system lymphoma, currently recruiting at Memorial Sloan…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Central Nervous System Lymphoma

Drugs mentioned

• MB-CART19.1

Snippet

Sponsor: Memorial Sloan Kettering Cancer Center | Conditions: Primary Central Nervous System (CNS) Lymphoma, Secondary Central Nervous System Lymphoma | Phase 1 | Status: RECRUITING